V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 30079426 | 30090106 | null | 91.95 | Palliative (P) | 2019-06-30 | 2019-06-30 | 111 Trial (formerly BEP 111) | 02 | null | CISPLATIN + VINORELBINE | 101793962 |
| 30122561 | 30091048 | 1.74 | 79 | null | 2020-01-24 | 2020-01-24 | 111 Trial (formerly BEP 111) | 02 | N | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE | 100315075 |
| 30122851 | 30091057 | 1.76 | 94.1 | Curative (C) | 2020-09-26 | 2020-10-08 | 111 Trial (formerly BEP 111) | 02 | null | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE | 101671833 |
| 30138355 | 30091334 | 1.85 | 65 | Palliative (P) | null | 2017-05-28 | 111 Trial (formerly BEP 111) | 02 | N | IVA | 100951576 |
| 30174040 | 30091946 | 1.68 | 71 | Curative (C) | 2018-05-02 | 2018-05-09 | 111 Trial (formerly BEP 111) | 02 | null | ERLOTINIB | 101642481 |
| 80048334 | 80050052 | 1.78 | 81.4 | Adjuvant (A) | 2019-03-06 | 2019-03-06 | A-PREDICT TRIAL | N | N | CARBOPLATIN + PEMBROLIZUMAB + PEMETREXED | 100969075 |
| 80043022 | 80047622 | 1.64 | 13.3 | null | 2019-02-08 | 2019-02-11 | A-PREDICT TRIAL | N | N | ENZALUTAMIDE | 101109149 |
| 70074809 | 70099999 | 1.4 | 55.3 | Curative (C) | 2017-12-20 | 2018-03-12 | A2G trial Asparaginase | 02 | N | NOT MATCHED | 100164790 |
| 70079038 | 70181751 | null | null | Curative (C) | 2019-05-11 | 2019-08-30 | A2G trial Asparaginase | 02 | N | NOT MATCHED | 101529921 |
| 70075281 | 70155977 | 1.54 | 58.5 | Neo-adjuvant (N) | 2017-10-09 | 2017-11-12 | A2G trial Asparaginase | 02 | N | CISPLATIN + GEMCITABINE + RITUXIMAB | 101493128 |
| 70074961 | 70155874 | 1.71 | null | null | 2018-11-19 | 2018-11-22 | A2G trial Asparaginase | 02 | null | NOT MATCHED | 100030200 |
| 70073943 | 70133010 | 1.69 | 57.25 | 03 | 2019-11-12 | 2019-11-15 | A2G trial Asparaginase | 02 | N | BRENTUXIMAB | 101802289 |
| 20055534 | 20086641 | 1.67 | 76 | Palliative (P) | 2019-03-31 | 2019-04-16 | ABC-08 Trial | 02 | N | CAPECITABINE + OXALIPLATIN + TRASTUZUMAB | 100077497 |
| 20108852 | 20087195 | 1.82 | 96 | 03 | 2019-02-02 | 2019-03-01 | ABC-08 Trial | 02 | N | CABAZITAXEL | 100885043 |
| 20152813 | 20087841 | 1.73 | 84.7 | Adjuvant (A) | 2021-02-04 | 2021-02-20 | ABC-08 Trial | 02 | N | ACELARATE TRIAL | 100598057 |
| 20029260 | 20085737 | 1.58 | 53.6 | Palliative (P) | 2017-11-05 | 2017-11-07 | ABC-08 Trial | N | N | PAZOPANIB | 100332183 |
| 40169506 | 40316449 | 1.56 | 99 | null | 2020-10-06 | 2020-10-14 | ABEMACICLIB + DENOSUMAB + FULVESTRANT | 02 | null | ABEMACICLIB + FULVESTRANT | 101376458 |
| 40162821 | 40197265 | 1.64 | 75.8 | Palliative (P) | 2020-01-31 | 2020-03-15 | ABEMACICLIB + DENOSUMAB + FULVESTRANT | 02 | N | ABEMACICLIB + FULVESTRANT | 101647223 |
| 40166719 | 40281679 | 1.61 | 61.2 | null | 2019-12-24 | 2020-01-18 | ABEMACICLIB + DENOSUMAB + FULVESTRANT | 02 | null | ABEMACICLIB + FULVESTRANT | 100493032 |
| 40167659 | 40282038 | 1.65 | 74.9 | null | 2019-02-22 | 2019-02-23 | ABEMACICLIB + DENOSUMAB + FULVESTRANT | 02 | null | ABEMACICLIB + FULVESTRANT | 101226279 |
| 40166034 | 40250111 | 1.74 | 63 | null | 2017-01-19 | 2017-02-10 | ABEMACICLIB + DENOSUMAB + FULVESTRANT | 02 | null | ABEMACICLIB + FULVESTRANT | 100894350 |
| 10401421 | 10056997 | 1.73 | 58.4 | Palliative (P) | 2019-05-04 | 2019-05-04 | ABEMACICLIB + FULVESTRANT | 02 | N | CHLORAMBUCIL + RITUXIMAB | 101610417 |
| 10435409 | 10041738 | 1.67 | 43.9 | Curative (C) | null | 2019-04-09 | ABEMACICLIB + FULVESTRANT | N | null | CISPLATIN + CAPECITABINE + EPIRUBICIN | 101610498 |
| 110041082 | 110008669 | 1.51 | 0 | null | 2019-10-28 | 2020-04-16 | ABEMACICLIB + FULVESTRANT | 02 | null | IPILIMUMAB + NIVOLUMAB | 101692930 |
| 110040094 | 110009648 | 1.83 | 88.9 | Neo-adjuvant (N) | 2017-05-13 | 2017-05-25 | ABEMACICLIB + FULVESTRANT | N | N | TEMOZOLOMIDE | 100111249 |
| 10425011 | 10041454 | 0 | 81.25 | Palliative (P) | 2018-11-28 | 2018-12-04 | ABEMACICLIB + FULVESTRANT | 02 | N | AML17 TRIAL | 100617632 |
| 10447690 | 10041978 | 1.75 | 95.7 | Palliative (P) | 2019-06-23 | 2019-06-28 | ABEMACICLIB + FULVESTRANT | 02 | N | MYELOMA XII TRIAL | 100413450 |
| 10028896 | 10042589 | 1.82 | 112.4 | null | 2017-12-17 | 2018-01-12 | ABEMACICLIB + FULVESTRANT | 02 | null | THALIDOMIDE | 101710164 |
| 10396318 | 10056958 | 1.63 | 80 | Curative (C) | 2019-08-16 | 2019-11-28 | ABEMACICLIB + FULVESTRANT | 02 | N | ABEMACICLIB | 100462041 |
| 40168861 | 40120963 | 1.55 | 81.2 | Neo-adjuvant (N) | 2018-03-15 | 2018-03-29 | ABEMACICLIB + FULVESTRANT | 02 | N | ABEMACICLIB + FULVESTRANT | 100217102 |
| 10403126 | 10057016 | 1.82 | null | null | 2019-04-22 | 2019-05-07 | ABEMACICLIB + FULVESTRANT | 02 | null | DOXORUBICIN + OLARATUMAB | 100034244 |
| 10433229 | 10057383 | null | 72.2 | Adjuvant (A) | 2018-04-11 | 2018-04-26 | ABEMACICLIB + FULVESTRANT | 02 | N | GEMCITABINE + NAB-PACLITAXEL | 100198833 |
| 10446379 | 10057541 | 1.5 | 66.4 | null | 2021-10-14 | 2021-10-21 | ABEMACICLIB + FULVESTRANT | 02 | null | CVP R | 100803816 |
| 10448026 | 10057554 | 1.7 | 73.1 | Adjuvant (A) | 2022-02-06 | 2022-02-13 | ABEMACICLIB + FULVESTRANT | 02 | N | DASATINIB | 100036696 |
| 10454792 | 10057606 | 1.84 | 83.35 | Palliative (P) | 2018-07-29 | 2018-08-01 | ABEMACICLIB + FULVESTRANT | 2 | N | BENDAMUSTINE + OBINUTUZUMAB | 101314395 |
| 10457276 | 10057634 | 1.62 | 68.6 | Palliative (P) | 2018-01-06 | 2018-01-07 | ABEMACICLIB + FULVESTRANT | 02 | N | CARBOPLATIN + DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100101604 |
| 10466573 | 10057722 | 1.55 | 56.4 | Palliative (P) | 2017-12-25 | 2018-01-15 | ABEMACICLIB + FULVESTRANT | 02 | N | BEXAROTENE | 100469967 |
| 10395753 | 10058214 | 1.67 | 83 | 03 | 2020-01-19 | 2020-01-23 | ABEMACICLIB + FULVESTRANT | 02 | N | CYCLOPHOSPHAMIDE + CYTARABINE + DOXORUBICIN + METHOTREXATE + RITUXIMAB + VINCRISTINE | 101611413 |
| 10465398 | 10065291 | 1.64 | 92.1 | Palliative (P) | 2018-11-23 | 2018-11-30 | ABEMACICLIB + FULVESTRANT | null | N | SORAFENIB | 101150734 |
| 10299345 | 10065542 | 0 | 50.8 | null | 2022-01-28 | 2022-03-07 | ABEMACICLIB + FULVESTRANT | 02 | null | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 100047422 |
| 10458298 | 10069538 | 1.82 | 71.6 | null | 2020-06-15 | 2020-06-29 | ABEMACICLIB + FULVESTRANT | 99 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 101103577 |
| 10189203 | 10071399 | 1.7 | 83 | Palliative (P) | 2022-04-18 | 2022-04-18 | ABEMACICLIB + FULVESTRANT | 02 | N | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 100076185 |
| 10194595 | 10073052 | null | 79.1 | null | 2018-09-08 | 2020-01-18 | ABEMACICLIB + FULVESTRANT | 02 | null | BENDAMUSTINE + OBINUTUZUMAB | 100647434 |
| 100040254 | 100181081 | 1.59 | 63.2 | null | null | 2017-10-18 | ABEMACICLIB + FULVESTRANT | null | null | CARBOPLATIN + PACLITAXEL + PEMBROLIZUMAB | 100804352 |
| 40027871 | 40122211 | 1.58 | 97.8 | Neo-adjuvant (N) | 2020-01-19 | 2020-01-19 | ABEMACICLIB + FULVESTRANT | 02 | N | ABEMACICLIB + FULVESTRANT | 101451338 |
| 40026177 | 40122168 | null | 106 | Adjuvant (A) | null | 2018-01-15 | ABEMACICLIB + FULVESTRANT | 99 | N | ABEMACICLIB + FULVESTRANT | 101076072 |
| 40002025 | 40121626 | 0 | 112.1 | Palliative (P) | 2021-07-24 | 2021-08-11 | ABEMACICLIB + FULVESTRANT | 02 | null | ABEMACICLIB + FULVESTRANT | 100991378 |
| 40001373 | 40121611 | 0.65 | 63.9 | null | 2021-06-25 | 2021-07-12 | ABEMACICLIB + FULVESTRANT | 02 | N | ABEMACICLIB + FULVESTRANT | 101495115 |
| 20218158 | 20170059 | 1.61 | 59 | Palliative (P) | 2020-11-21 | 2020-12-02 | ABEMACICLIB + FULVESTRANT | 02 | N | BEVACIZUMAB + CAPECITABINE + OXALIPLATIN | 100994352 |
| 110040554 | 110008655 | 1.59 | 0 | null | null | 2018-08-13 | ABEMACICLIB + FULVESTRANT | 02 | null | TRIAL UNSPECIFIED | 100541538 |